2 weeks Ago By ABMN Staff
HB Wealth Management LLC boosted its holdings in Edwards Lifesciences Co. ( NYSE:EW – Free Report ) by 37.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
The firm owned 16,422 shares of the medical research company’s stock after purchasing an additional 4,493 shares during the quarter. HB Wealth Management LLC’s holdings in Edwards Lifesciences were worth $1,517,000 at the end of the most recent quarter. Other institutional investors have also recently bought and sold shares of the company.
1834 Investment Advisors Co. raised its stake in shares of Edwards Lifesciences by 9.6% in the second quarter.
1834 Investment Advisors Co. now owns 8,503 shares of the medical research company’s stock worth $785,000 after purchasing an additional 747 shares during the last quarter. Kintegral Advisory LLC lifted its stake in Edwards Lifesciences by 123.
0% during the 2nd quarter. Kintegral Advisory LLC now owns 72,923 shares of the medical research company’s stock valued at $6,736,000 after acquiring an additional 40,223 shares in the last quarter. Conning Inc.
boosted its holdings in Edwards Lifesciences by 6.2% during the 2nd quarter. Conning Inc.
now owns 4,769 shares of the medical research company’s stock worth $441,000 after acquiring an additional 278 shares during the last quarter. Simmons Bank grew its stake in shares of Edwards Lifesciences by 2.4% in the 2nd quarter.
Simmons Bank now owns 39,220 shares of the medical research company’s stock worth $3,623,000 after acquiring an additional 932 shares in the last quarter. Finally, Checchi Capital Advisers LLC raised its holdings in shares of Edwards Lifesciences by 3.3% in the second quarter.
Checchi Capital Advisers LLC now owns 6,719 shares of the medical research company’s stock valued at $621,000 after purchasing an additional 212 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.
Edwards Lifesciences Stock Performance NYSE:EW opened at $70.12 on Friday. Edwards Lifesciences Co.
has a 52-week low of $58.93 and a 52-week high of $96.12.
The business’s fifty day moving average is $77.91 and its 200 day moving average is $85.02.
The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.
71. The firm has a market cap of $42.25 billion, a price-to-earnings ratio of 30.
22, a PEG ratio of 2.57 and a beta of 1.11.
Insider Buying and Selling at Edwards Lifesciences In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, June 12th.
The stock was sold at an average price of $87.54, for a total transaction of $437,700.00.
Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $4,108,777.44. The transaction was disclosed in a document filed with the SEC, which is available through this link .
In other news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.
50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35.
The transaction was disclosed in a filing with the SEC, which is available at this hyperlink . Also, VP Donald E. Bobo, Jr.
sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total value of $437,700.
00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $4,108,777.44.
The disclosure for this sale can be found here . Insiders sold a total of 16,250 shares of company stock valued at $1,321,988 in the last three months. Company insiders own 1.
29% of the company’s stock. Analyst Upgrades and Downgrades A number of equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Edwards Lifesciences from $103.
00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, July 25th. TD Cowen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $100.
00 to $70.00 in a research report on Thursday, July 25th. Piper Sandler cut their price objective on Edwards Lifesciences from $88.
00 to $73.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th.
Finally, Daiwa Capital Markets upgraded shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Fourteen equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.
com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.10. Read Our Latest Research Report on EW About Edwards Lifesciences ( Free Report ) Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally.
It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. Featured Articles Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co.
( NYSE:EW – Free Report ). Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
